Modern management of tuberculosis. 1979

R A Promisloff, and R F Johnston

UI MeSH Term Description Entries
D007538 Isoniazid Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. Isonicotinic Acid Hydrazide,Ftivazide,Isonex,Isonicotinic Acid Vanillylidenehydrazide,Phthivazid,Phthivazide,Tubazide,Acid Vanillylidenehydrazide, Isonicotinic,Hydrazide, Isonicotinic Acid,Vanillylidenehydrazide, Isonicotinic Acid
D008297 Male Males
D010131 Aminosalicylic Acid An antitubercular agent often administered in association with ISONIAZID. The sodium salt of the drug is better tolerated than the free acid. 4-Aminosalicylic Acid,p-Aminosalicylic Acid,para-Aminosalicylic Acid,Alumino-4-Aminosalicylic Acid,Pamisyl,Rezipas,p-Aminosalicylic Acid Monolithium Salt,p-Aminosalicylic Acid Monopotassium Salt,p-Aminosalicylic Acid Monosodium Salt,p-Aminosalicylic Acid, Aluminum (2:1) Salt,p-Aminosalicylic Acid, Calcium (2:1) Salt,p-Aminosalicylic Acid, Monosodium Salt, Dihydrate,4 Aminosalicylic Acid,Acid, Aminosalicylic,Alumino 4 Aminosalicylic Acid,p Aminosalicylic Acid,p Aminosalicylic Acid Monolithium Salt,p Aminosalicylic Acid Monopotassium Salt,p Aminosalicylic Acid Monosodium Salt,para Aminosalicylic Acid
D011718 Pyrazinamide A pyrazine that is used therapeutically as an antitubercular agent. Tisamid
D002648 Child A person 6 to 12 years of age. An individual 2 to 5 years old is CHILD, PRESCHOOL. Children
D003523 Cycloserine Antibiotic substance produced by Streptomyces garyphalus. R-4-Amino-3-isoxazolidinone,Seromycin
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D004977 Ethambutol An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863) Dexambutol,EMB-Fatol,EMB-Hefa,Etambutol Llorente,Ethambutol Hydrochloride,Etibi,Miambutol,Myambutol,EMB Fatol,EMB Hefa,Hydrochloride, Ethambutol,Llorente, Etambutol
D005000 Ethionamide A second-line antitubercular agent that inhibits mycolic acid synthesis. Amidazine,Ethioniamide,Trecator,Trecator-SC,Trecator SC

Related Publications

R A Promisloff, and R F Johnston
May 1969, Journal of the National Medical Association,
R A Promisloff, and R F Johnston
November 1965, Applied therapeutics,
R A Promisloff, and R F Johnston
January 1995, Neurosurgery,
R A Promisloff, and R F Johnston
July 1955, Journal of the National Medical Association,
R A Promisloff, and R F Johnston
January 1955, Medicine illustrated,
R A Promisloff, and R F Johnston
August 1955, The Illinois medical journal,
R A Promisloff, and R F Johnston
May 2000, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
R A Promisloff, and R F Johnston
January 1979, Revista clinica espanola,
R A Promisloff, and R F Johnston
January 1977, Comprehensive therapy,
R A Promisloff, and R F Johnston
August 1954, Annals of internal medicine,
Copied contents to your clipboard!